Plenty Of Room For More Obesity Drugs, Says Boehringer, As Survodutide Enters Phase III

Boehringer Ingelheim is playing catch-up with Novo Nordisk and Lilly in obesity, but is hoping a higher dose and a more patient-friendly titration can help it prove that survodutide is a contender.